Latest News

Sep 23, 2021
Lytix Biopharma strengthens patent protection of lead candidate LTX-315 in the US
Aug 27, 2021
Lytix Biopharma second quarter and first half of 2021 results: Fueled to target the US cancer market
Aug 23, 2021
Lytix Biopharma presents first half and second quarter 2021 results, Friday 27 August
Jul 15, 2021
Lytix Biopharma initiates the Phase II combination study in the US with LTX-315 and Pembrolizumab in patients with solid tumors